Reviewing Hikma Pharmaceuticals (OTCMKTS:HKMPF) & Ernexa Therapeutics (NASDAQ:ERNA)

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Ernexa Therapeutics (NASDAQ:ERNA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and Ernexa Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	$3.13 billion	1.47	$359.00 million	N/A	N/A
Ernexa Therapeutics	$488,000.00	25.69	-$44.54 million	($3.01)	-0.54

Hikma Pharmaceuticals has higher revenue and earnings than Ernexa Therapeutics.

Profitability

This table compares Hikma Pharmaceuticals and Ernexa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	N/A	N/A	N/A
Ernexa Therapeutics	N/A	N/A	-682.08%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Hikma Pharmaceuticals and Ernexa Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0	0	1	0	3.00
Ernexa Therapeutics	1	0	0	0	1.00

Risk & Volatility

Hikma Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.72, suggesting that its stock price is 472% more volatile than the S&P 500.

Insider and Institutional Ownership

70.6% of Ernexa Therapeutics shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Hikma Pharmaceuticals beats Ernexa Therapeutics on 5 of the 9 factors compared between the two stocks.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.